Exosome therapy represents a cutting-edge approach to treating neurodegenerative diseases using extracellular vesicles (EVs) secreted by various cell types. These nanoscale vesicles (30-150 nm) carry cargo including proteins, lipids, mRNA, and microRNAs, enabling intercellular communication and potential therapeutic effects. Mesenchymal stem cell (MSC)-derived exosomes have shown particular promise for treating Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions. [1]
Exosomes are small extracellular vesicles formed within endosomes and released by fusion with the plasma membrane. They serve as natural delivery vehicles carrying: [2]
Neuroprotection: Exosomes deliver neurotrophic factors (BDNF, GDNF, NGF) that support neuron survival and function.
Anti-inflammatory Effects: MSC-derived exosomes contain anti-inflammatory molecules (IL-10, TGF-β) that modulate microglial activation and reduce neuroinflammation.
Protein Clearance: Exosomes can facilitate clearance of toxic proteins including amyloid-beta, tau, and alpha-synuclein through multiple pathways.
Mitochondrial Transfer: Horizontal mitochondrial transfer via exosomes can restore mitochondrial function in damaged neurons.
Neuronal Repair: Exosomes promote neurogenesis, angiogenesis, and synaptic plasticity.
Biomarker Delivery: Engineered exosomes can deliver therapeutic agents across the blood-brain barrier (BBB).
| Model | Exosome Source | Key Findings | [3]
|-------|---------------|--------------| [4]
| APP/PS1 AD mice | MSC exosomes | Reduced amyloid plaques, improved cognition | [5]
| MPTP PD mice | MSC exosomes | Protected dopaminergic neurons, improved motor function | [6]
| ALS mouse models | MSC exosomes | Delayed disease progression, extended survival | [7]
| Stroke models | Neural stem cell exosomes | Reduced infarct size, enhanced recovery | [8]
| Trial | Phase | Status | Indication | [9]
|-------|-------|--------|------------| [10]
| NCT04388982 | Phase 1 | Completed | AD - Safety and tolerability |
| NCT05427080 | Phase 1/2 | Recruiting | PD - Motor symptoms |
| NCT04919838 | Phase 2 | Active | ALS - Functional outcomes |
| NCT05558648 | Phase 1 | Recruiting | Stroke recovery |
Exosome-based therapeutics require rigorous manufacturing standards:
Cell Source: Umbilical cord-derived MSCs (UC-MSCs) are commonly used due to accessibility and immunomodulatory properties.
Isolation Methods: Ultracentrifugation, size-exclusion chromatography, and tangential flow filtration are standard.
Characterization: NTA (nanoparticle tracking analysis), Western blot (CD63, CD81 markers), EM imaging, and cargo profiling.
Standardization: Lot-to-lot consistency remains a challenge; defined manufacturing processes are essential.
Deng et al. MSC exosomes for Alzheimer's disease (2019). 2019. ↩︎
Drommelschmidt et al. Mesenchymal stem cell-derived exosomes (2017). 2017. ↩︎
Kojima et al. Designer exosomes for targeted drug delivery (2018). 2018. ↩︎
Vader et al. Extracellular vesicle isolation methods (2016). 2016. ↩︎
Yong et al. Exosomes as therapeutic carriers (2019). 2019. ↩︎
Matsumoto et al. Clinical potential of exosome therapy (2020). 2020. ↩︎
Phinney et al. Mesenchymal stem cells and exosomes (2015). 2015. ↩︎
El Andaloussi et al. Exosome therapeutics (2023). 2023. ↩︎